Editas Medicine GAAP EPS of -$0.28 beats by $0.03, revenue of $7.54M beats by $2.6M
Source: SeekingAlpha
2025-11-10 07:19:56 ET
More on Editas Medicine
- Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
- Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar Call
- Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar Transcript
- Gene editing therapy companies rise on word of streamlined FDA approval process
- Seeking Alpha’s Quant Rating on Editas Medicine
Read the full article on Seeking Alpha
For further details see:
Editas Medicine GAAP EPS of -$0.28 beats by $0.03, revenue of $7.54M beats by $2.6M
Editas Medicine Inc.
NASDAQ: EDIT
EDIT Trading
6.96% G/L:
$2.2301 Last:
855,013 Volume:
$2.11 Open:
EDIT Latest News
January 28, 2026 08:05:23 am
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
November 10, 2025 07:00:00 am
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
November 03, 2025 09:00:00 am
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
EDIT Stock Data
$174,737,401
95,568,668
0.4%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
